Practice Areas & Industries: Duane Morris LLP

 




Products Liability and Toxic TortsReturn to Practice Areas & Industries

Group Profile Lawyers in this Group Offices Locations for this Group
 

Practice/Industry Group Overview

Clients, ranging from some of the world's largest manufacturers and insurance companies to startup companies and individual inventors, turn to Duane Morris for counsel and representation regarding products liability and toxic torts. Duane Morris has for many years worked with clients to develop cost containment and strategic litigation plans resulting in high-level representation without fear of wildly escalating costs.

Duane Morris has many lawyers with extensive trial experience in the products liability and toxic torts arenas. As one of the 100 largest law firms in the world, Duane Morris utilizes industry-leading technology and IT professionals to efficiently and effectively handle client data needs through secure extranets and other means. In addition, our firm's breadth of capabilities and geographic footprint help us to assist clients with issues touching a range of legal disciplines in jurisdictions across the United States and around the world.

Duane Morris' experience includes product class actions, mass tort defense, and service on clients' national trial teams in federal, state and multidistrict litigation. In fact, we serve as National Coordinating Counsel (NCC) for huge, multinational manufacturers, and our lawyers have been published and quoted on best practices regarding the use of NCC.

The firm has working relationships with an extensive group of well qualified, independent and trial-tested consultants and expert witnesses, as well as experience in developing experts, and handling Daubert and Frye hearings in multiple jurisdictions. Our trial lawyers also work arm-in-arm with our Appellate Practice Group to provide sophisticated approaches to appellate issues faced by our clients in products liability matters.


 

Services Available

Our lawyers have defended a wide variety of products manufactured, distributed, sold or insured by our clients. We also counsel clients on regulatory, labeling, packaging and marketing issues to help manage risk and avoid litigation. We advise clients on product safety compliance, reporting, recalls and penalty proceedings before the U.S. Consumer Product Safety Commission (CPSC), the Food and Drug Administration (FDA) and their state counterparts, and other regulatory agencies.

Range of Experience

Areas in which our attorneys have experience include:

Food, Drugs and Medical Devices

  • Pharmaceuticals
  • Vitamins
  • Dietary supplements
  • Diet drugs
  • Medical devices
  • Surgical implants
  • Surgical tools
  • Orthopedic devices
  • Hospital equipment and medical supplies
  • Clinical and genetic laboratory testing
  • Dental devices and equipment
  • Food and food processing

Consumer Products

  • Sporting goods
  • Recreational equipment
  • Toys
  • Weapons and body armor
  • Hair care and cosmetics
  • Cleansers
  • Clothing

Toxic Torts

  • Asbestos
  • Silica
  • Amorphous silica
  • Benzene
  • Pesticides
  • Mold
  • Chemicals, paints and coatings
  • Cleaners and degreasers
  • Ground Water Contamination

Vehicles and Equipment

  • Automobiles, trucks and their components
  • Landscaping and grounds maintenance equipment
  • Energy generation equipment
  • Construction and farm equipment
  • Printing equipment
  • Heating equipment
  • Industrial equipment

 
 
Articles Authored by Lawyers at this office:

FACT Act Promises Transparency in Bankruptcy Trust Claims and Payments for Asbestos Exposure
, November 22, 2013
Asbestos defendants are one step closer to greater transparency regarding the often illusive bankruptcy trust claims and payments. On Wednesday, November 13, 2013, the U.S. House of Representatives passed H.R. 982, the Furthering Asbestos Claim Transparency (FACT) Act by a 221-199 vote. FACT would...

FDA Proposed Rule Would Require Generics to Update Label Warnings Even Before Branded Pharmaceuticals Do
, November 15, 2013
On Wednesday, November 13, 2013, the U.S. Food and Drug Administration (FDA) will publish a proposed rule in the Federal Register that will mandate that generic drug firms update their labels for drugs under approved Abbreviated New Drug Applications (ANDAs) to add warnings, precautions, adverse...